Answers are grounded in this paper and cite their sources.
In the tumor microenvironment (TME), the potential role of B cells in tumor immunotherapy has not been paid enough attention for a long time. In recent years, B cells have been widely infiltrated in the TME of a variety of solid tumors, and their functional status significantly affects tumor progression and immune response. B cells can inhibit tumor progression through inducing and maintaining tertiary lymphoid structures and lympho-myeloid aggregates, Ab-dependent anti-tumor effects, Ag presentation, T cell activation, and direct anti-tumor effects. It can also inhibit anti-tumor immune response by producing tumor-promoting antibodies, secreting immunosuppressive cytokines and chemokines, and expressing immune checkpoint molecules. The factors that influence B cell differentiation and function have not been fully elucidated. The complete analysis of these complex factors is essential for designing more precise B-cell-targeted therapies. In addition, based on their dual effects, immunotherapy strategies targeting B cells have developed rapidly. B cells have become an important target for a new generation of immunotherapy. This review systematically expounds on the dual regulatory mechanisms of B cells in the occurrence and development of tumors, analyzes the key factors affecting their functions, and explores the clinical application prospects of targeted B cell therapy to aid in the precise immunotherapy of tumors.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: